Osnat Bohana‐Kashtan

1.3k total citations
21 papers, 597 citations indexed

About

Osnat Bohana‐Kashtan is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Osnat Bohana‐Kashtan has authored 21 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 8 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Osnat Bohana‐Kashtan's work include Acute Lymphoblastic Leukemia research (5 papers), Immunotherapy and Immune Responses (4 papers) and Complement system in diseases (4 papers). Osnat Bohana‐Kashtan is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), Immunotherapy and Immune Responses (4 papers) and Complement system in diseases (4 papers). Osnat Bohana‐Kashtan collaborates with scholars based in United States, Israel and Italy. Osnat Bohana‐Kashtan's co-authors include Zvi Fishelson, Curt I. Civin, Sarah Kraus, Michael Kirschfink, Stefanie Ziegler, K. Jurianz, Helena Garcia Schüler, Lorenzo A. Pinna, Yoav Paas and Richard Hildreth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Osnat Bohana‐Kashtan

20 papers receiving 579 citations

Peers

Osnat Bohana‐Kashtan
Robert P. Stephan United States
Julie S. Yuan Canada
Angela Stoddart United States
Fraser McBlane United States
L. Remels Belgium
DD Hickstein United States
M Crawford Australia
Hélia Neves Portugal
A. Miyajima Japan
Lucio Gómez Spain
Robert P. Stephan United States
Osnat Bohana‐Kashtan
Citations per year, relative to Osnat Bohana‐Kashtan Osnat Bohana‐Kashtan (= 1×) peers Robert P. Stephan

Countries citing papers authored by Osnat Bohana‐Kashtan

Since Specialization
Citations

This map shows the geographic impact of Osnat Bohana‐Kashtan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osnat Bohana‐Kashtan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osnat Bohana‐Kashtan more than expected).

Fields of papers citing papers by Osnat Bohana‐Kashtan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osnat Bohana‐Kashtan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osnat Bohana‐Kashtan. The network helps show where Osnat Bohana‐Kashtan may publish in the future.

Co-authorship network of co-authors of Osnat Bohana‐Kashtan

This figure shows the co-authorship network connecting the top 25 collaborators of Osnat Bohana‐Kashtan. A scholar is included among the top collaborators of Osnat Bohana‐Kashtan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osnat Bohana‐Kashtan. Osnat Bohana‐Kashtan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Jun, Stephanie Sun, Geoffrey L. Uy, et al.. (2019). CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. Blood. 134(Supplement_1). 2745–2745. 3 indexed citations
2.
Uy, Geoffrey L., Tapan M. Kadia, Wendy Stock, et al.. (2019). CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. Blood. 134(Supplement_1). 2630–2630. 8 indexed citations
3.
4.
5.
Xia, Jun, Stephanie Sun, Geoffrey L. Uy, et al.. (2018). The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models. Blood. 132(Supplement 1). 2700–2700. 2 indexed citations
6.
McGill, Trevor J., Osnat Bohana‐Kashtan, Jonathan Stoddard, et al.. (2017). Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation. Translational Vision Science & Technology. 6(3). 17–17. 43 indexed citations
7.
Sherman, Daniel, Alina Shitrit, Efrat Ben‐Zeev, et al.. (2012). 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic & Medicinal Chemistry Letters. 22(20). 6460–6468. 30 indexed citations
8.
Becker, Oren M., Vered Behar, Osnat Bohana‐Kashtan, et al.. (2011). In vivo tumor growth inhibition by novel PKM2 cancer metabolism modulators.. Journal of Clinical Oncology. 29(15_suppl). 10530–10530.
9.
Behar, Vered, et al.. (2011). Abstract 4065: Modulation of cancer metabolism with novel PKM2 activators exerts anti-tumor activity. Cancer Research. 71(8_Supplement). 4065–4065. 1 indexed citations
10.
Morisot, Sebastien, Alan S. Wayne, Osnat Bohana‐Kashtan, et al.. (2010). High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia. 24(11). 1859–1866. 37 indexed citations
11.
Bohana‐Kashtan, Osnat, Sebastien Morisot, Richard Hildreth, et al.. (2009). Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand. The Journal of Immunology. 183(1). 696–705. 25 indexed citations
12.
Morisot, Sebastien, Alan S. Wayne, Osnat Bohana‐Kashtan, et al.. (2008). Leukemia Stem Cells (LSCs) Are Frequent in Childhood Precursor B Acute Lymphoblastic Leukemia (ALL).. Blood. 112(11). 1354–1354. 3 indexed citations
13.
Georgantas, Robert W., Osnat Bohana‐Kashtan, & Curt I. Civin. (2006). Ex Vivo Soluble Fas Ligand Treatment of Donor Cells to Selectively Reduce Murine Acute Graft Versus Host Disease. Transplantation. 82(4). 471–478. 17 indexed citations
14.
Bohana‐Kashtan, Osnat, Lorenzo A. Pinna, & Zvi Fishelson. (2005). Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. European Journal of Immunology. 35(6). 1939–1948. 35 indexed citations
15.
Bohana‐Kashtan, Osnat & Curt I. Civin. (2005). Profiling Tumor Counterattack: Do Fas Ligand–Containing Microvesicles Reduce Anticancer Immunity?. Clinical Cancer Research. 11(3). 968–970. 7 indexed citations
16.
Bohana‐Kashtan, Osnat. (2004). Cell signals transduced by complement. Molecular Immunology. 41(6-7). 583–597. 121 indexed citations
17.
Bohana‐Kashtan, Osnat & Curt I. Civin. (2004). Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance. Stem Cells. 22(6). 908–924. 47 indexed citations
18.
Jurianz, K., Stefanie Ziegler, Helena Garcia Schüler, et al.. (1999). Complement resistance of tumor cells: basal and induced mechanisms. Molecular Immunology. 36(13-14). 929–939. 173 indexed citations
19.
Paas, Yoav, Osnat Bohana‐Kashtan, & Zvi Fishelson. (1999). Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells. Immunopharmacology. 42(1-3). 175–185. 28 indexed citations
20.
Bohana‐Kashtan, Osnat, Yoav Paas, & Zvi Fishelson. (1998). Partial characterization of the C9 ectoprotein kinase of K562 cells. Molecular Immunology. 35(6-7). 346–346. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert P. Stephan Breakdown of academic impact, for papers by Julie S. Yuan Breakdown of academic impact, for papers by Angela Stoddart Breakdown of academic impact, for papers by Fraser McBlane Breakdown of academic impact, for papers by L. Remels Breakdown of academic impact, for papers by DD Hickstein Breakdown of academic impact, for papers by M Crawford Breakdown of academic impact, for papers by Hélia Neves Breakdown of academic impact, for papers by A. Miyajima Breakdown of academic impact, for papers by Lucio Gómez
Rankless by CCL
2026